Algeria vs Palau: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Algeria
95.0%
in 2025
Palau
95.0%
in 2025
Algeria rank
37th
Palau rank
37th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Algeria
- Palau
How they compare
Algeria currently reports 95.0% against 95.0% in Palau, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Palau ahead.
Algeria ranks 37th and Palau ranks 37th of 192 countries.
Palau has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Algeria | Palau | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 12.5% | 12.5% | Palau |
| 2010s | 32.8% | 81.2% | 48.4% | Palau |
| 2020s | 84.8% | 86.0% | 1.2% | Palau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Algeria or Palau?
- Algeria, at 95.0% against 95.0% in Palau as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Algeria and Palau?
- 0.0%, with Algeria ahead.
- How many years of comparable data are there for Algeria and Palau?
- 18 years are reported by both, from 2008 to 2025.
- How do Algeria and Palau rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Algeria ranks 37th and Palau ranks 37th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.